Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: EC:2.6.1.2 (alanine aminotransferase)
26,722 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A comparison between recombinant immunoblot assay hepatitis C virus (HCV) first generation (RIBA-1) and second generation (RIBA-2) was made on 732 blood donors reactive by anti-HCV ELISA (Ortho Diagnostics System) by the Hepatitis Study Group of the French Society of Blood Transfusion. RIBA-2 results were correlated with ELISA ratio and ALT levels. The number of both reactive and nonreactive samples was higher with RIBA-2 than with RIBA-1, 252 (34%) compared to 224 (31%) for reactive samples, and 404 (55%) compared to 307 (42%) for nonreactive samples. C 22-3 and C 33-c reactivities were observed in 96 and 91% of the reactive samples, respectively. A total of 76 samples (11%) remained indeterminate by RIBA-2, 84% of them reacting only on C 100-3 antigen. A clear relationship between RIBA-2 results and both ELISA ratio and alanine aminotransferase (ALT) levels was demonstrated: 20% of samples with normal ALT level and 10% of samples with low ELISA ratio were reactive when 91% of samples with ALT greater than 2N and 69% of samples with high ELISA ratio were reactive. The totality of the 57 samples with both ALT greater than 2N and high ELISA ratio were reactive and 93% of samples with normal ALT level and low ELISA ratio were nonreactive.
...
PMID:Recombinant immunoblot assay first and second generations on 732 blood donors reactive for antibodies to hepatitis C virus by ELISA. The Hepatitis Study Group of the French Society of Blood Transfusion. 166 33

The recent cloning of the genome of hepatitis C virus (HCV) has allowed the detection of antibodies to HCV (anti-HCV) in human serum. The presence of serum antibodies to HCV often indicates active infection with HCV. We have assessed the serological and histological features in a group of alcoholic patients with chronic liver disease and have evaluated the possible etiologic role of HCV infection in the development of liver damage. Serum samples and liver biopsy specimens were obtained from 41 consecutive patients, all having a definite history of alcohol abuse and evidence of chronic hypertransaminasemia. Fifteen patients (37%) were positive for anti-HCV by ELISA, and 13 (86.6%) of them were also positive by RIBA. Eleven of these patients had histologic features of chronic active hepatitis (CAH), a lesion which is not known to be induced by excessive alcohol intake. No other possible causes of CAH were found, and CAH was not present in any of the anti-HCV negative patients. In patients with CAH, mean AST to ALT ratio was less than 1 (0.6), a finding which is characteristic of viral rather than alcoholic chronic liver disease. In conclusion, our study suggests that sporadic hepatitis C virus infection plays an etiologic role in the development of chronic active liver disease in a subgroup of alcoholic patients.
...
PMID:Serological and histological aspects of hepatitis C virus infection in alcoholic patients. 166 17

An epidemic of hepatitis C virus infection in plasmapheresis donors which occurred in 1985 in Gu-An county, Hebei province, was studied. A total of 3,496 persons in five villages were investigated. The prevalence rates of viral hepatitis and elevated ALT levels alone in plasmapheresis donors were 17.10% and 23.23%, respectively, which were significantly higher than these of whole blood donors and controls. 59 sera collected from plasmapheresis donors with viral hepatitis and elevated ALT levels alone were sent to the Centers for Disease Control, USA, for detection of anti-HCV with Chiron C100 (EIA). The positivity rates of anti-HCV were 97.06% and 100%, respectively, indicating that the epidemic was caused by hepatitis C virus.
...
PMID:[Epidemiological and serological study on hepatitis C virus infection in plasmapheresis donors]. 166 79

In order to evaluate the seroprevalence of anti-hepatitis C virus (HCV) antibody in rheumatoid arthritis (RA), where a high prevalence of false-positive anti-HCV reactions is reported, we studied 79 patients affected with RA. In these subjects we recorded some clinical and anamnestic data (history of blood transfusion, risk factors of liver disease, therapy) and determined, besides a few routine laboratory parameters including rheumatoid factor (RF), AST and ALT, the anti-HCV serology using the 1st (EIA, Ortho and Abbott; Neutralization test, Abbott; RIBA, Chiron-Ortho) and the 2nd generation tests (EIA, Ortho; RIBA, Chiron-Ortho). Four patients (of whom three were RF seronegative) were anti-HCV reactive by the 1st generation EIA tests (5.1%). According to the results of the confirmatory tests, and particularly of the 2nd generation, two patients resulted infected by HCV. These results do not confirm the previously reported high prevalence of false-positive anti-HCV reactions in RA, and demonstrated the usefulness of the 2nd generation tests in diagnosing the HCV infection.
...
PMID:[Prevalence of antibodies against hepatitis C virus in rheumatoid arthritis. Study using second-generation tests]. 166 11

To see whether the introduction of screening tests for post-transfusion non-A, non-B hepatitis (NANBH) in the UK would be worth while, the incidence of such hepatitis was assessed among patients receiving blood during operations at five hospitals served by the North London Blood Transfusion Centre. 387 patients, who each received blood or blood components from an average of 3 donors were followed up prospectively and blood samples were taken every 2 weeks for 3 months and then each month for a further 3 months. 229 patients also provided a sample at 12 months. All available patient and donor samples were tested for alanine aminotransferase concentrations and for antibody to hepatitis C virus (anti-HCV) by ELISA. Repeatedly anti-HCV positive samples were submitted to supplementary HCV assays. 1 of the 387 patients showed biochemical evidence of acute post-transfusion NANBH after exclusion of non-viral causes. Anti-HCV developed in this patient and the seroconversion was confirmed by recombinant immunoblot assay and polymerase chain reaction. Serum from 1 of the 8 donors whose blood he received was positive for anti-HCV by all three methods. In another patient HCV seroconversion was shown by ELISA but alanine aminotransferase concentrations remained normal throughout follow-up. His samples and those of his 2 donors were negative for HCV by the polymerase chain reaction. A third patient showed rises in alanine aminotransferase compatible with post-transfusion NANBH, but serology and polymerase chain reaction assays for HCV were negative for her samples and those of her donors. Anti-HCV reactivity likely to be false positive (negative by both confirmatory tests and no adverse effects in recipients) was seen in 6 of 1283 donors. This study, despite its being carried out in the part of the UK with the highest frequency of infectious markers in blood donations, has shown a very low incidence of post-transfusion NANBH.
...
PMID:Low incidence of non-A, non-B post-transfusion hepatitis in London confirmed by hepatitis C virus serology. 170 35

We evaluated oral ribavirin as therapy for chronic hepatitis C infection in a pilot study including 10 patients. Patients (7 men, 3 women; mean age 40 years, range 23-54) all had biopsy-proven chronic non-A, non-B hepatitis and were repeatedly positive for antibodies to hepatitis C virus. Treatment was with oral ribavirin 1000-1200 mg per day in two divided doses for 12 weeks. The median serum alanine aminotransferase concentration for all patients at enrollment was 3.15 mu kat/l (range 1.22-7.79) and decreased significantly (p less than 0.005) to 1.25 mu kat/l (0.78-2.04) after 12 weeks of treatment. Within 6 weeks of the end of treatment the median serum alanine aminotransferase concentration was not significantly different from that before treatment. Side-effects were mild and fully reversible after cessation of therapy. We conclude that ribavirin is the first drug to offer a potentially effective oral treatment for chronic hepatitis C. It should be further evaluated in controlled trials, possibly in combination with interferon alpha.
...
PMID:Ribavirin treatment for chronic hepatitis C. 171 40

There is evidence that hepatitis C virus (HCV) may be vertically transmitted from infected mothers to their children. To test this hypothesis, we prospectively studied 10 pregnant women at high risk from parenterally or sexually transmitted diseases with the polymerase chain reaction. HCV RNA was found in 8 newborn babies delivered by women who were anti-HCV seropositive, and persisted for 2-19 months of follow-up. Anti-HCV detected in 7 infants cleared by 9 months and remained undetectable thereafter. Serum alanine aminotransferase was raised in 3 infants. The findings provide evidence of vertical transmission of HCV and suggest that perinatal infection may initiate a silent disease process or chronic carrier state.
...
PMID:Vertical transmission of hepatitis C virus. 167 87

To clarify the prevalence of concurrent infection with hepatitis C virus (HCV), hepatitis B virus (HBV) and human T cell leukaemia virus (HTLV), we measured HCV antibody in the population of a district endemic for HBV and HTLV infection. Blood samples were collected in June 1990 from 579 inhabitants of four islands of Uwa Bay in the southwest of Ehime Prefecture in Japan. Anti-HCV antibody against C100-3 protein was detected using an enzyme-linked immunosorbent assay kit (Ortho Diagnostics). Thirteen of the 579 inhabitants (2.2%) were positive for anti-HCV, and this prevalence rate was not significantly different from the frequency of anti-HCV in Tokyo blood donors. A total of 11% (64 of 579) of the subjects were positive for HBsAg and 3.3% (19 of 579) were positive for anti-HTLV. These frequencies of HBsAg and anti-HTLV positivity were distinctly higher than the respective means of Japanese. All anti-HCV positive individuals were negative for HBsAg and anti-HTLV, while 54% (7 of 13) had increased alanine aminotransferase levels. These data suggest that the prevalence of HCV infection is not high even in an area endemic for HBV and HTLV infection.
...
PMID:Prevalence of hepatitis C virus antibody in an area endemic for hepatitis B virus and human T cell leukaemia virus. 168 26

An established chimpanzee model of parenterally-transmitted non-A, non-B hepatitis was used to define virus-specific immune response patterns in acutely and persistently infected animals. Serial bleedings were obtained from 23 chimpanzees that had been experimentally infected with an isolate of hepatitis C virus, originally recovered from contaminated lots of factor VIII (antihemophilic) materials. Sera were assayed for the presence of antihepatitis C virus by a newly developed radioimmunoassay procedure that incorporated recombinant DNA-expressed viral antigen as a reagent. Twenty-one of 23 hepatitis C virus infected animals were shown to acquire antihepatitis C virus, most within 2-8 weeks after the major peak of alanine aminotransferase activity. All chimpanzees with biochemical, electron microscopic, and histological evidence of chronic disease clearly acquired antibody; 14 of 16 animals observed through the acute phase of disease were also shown to acquire antibody. A booster effect or anamnestic response was noted in two chimpanzees (one of which was negative for antihepatitis C virus following the acute phase of disease) after challenge with hepatitis C virus. Antihepatitis C virus was not neutralizing, because some animals with high levels of antibody were also shown to have high titers of circulating hepatitis C virus. The development and maintenance of anti-hepatitis C virus appears to reflect concomitant virus replication and high potential for infectivity.
...
PMID:Parenterally transmitted non-A, non-B hepatitis: virus-specific antibody response patterns in hepatitis C virus-infected chimpanzees. 169 46

This paper discusses the progress of enzyme diagnosis by different examples. These include: the requirement for improved enzymological screening, despite the introduction of a test for hepatitis C; the imbalance between the popularity of "unexplained chronic aminotransferase elevations" and efforts to solve the inherent problems; the inadequate attempts to use the metabolic changes in the hepatocytes to improve diagnosis, prognosis, and pathophysiological understanding of viral liver diseases; the remarkable investigations into the 2'-5'-oligoadenylate synthetase for better control of interferon therapy in chronic viral hepatitis; the use of enzymes as markers of etiology, particularly for the detection of alcohol induced liver diseases; the continuing preference for the aminotransferases in this scenario although the ratios of aspartate aminotransferase over alanine aminotransferase, or of mitochondrial aspartate aminotransferase over total aspartate aminotransferase activity, largely depend on the severity and intralobular localization of damage and the stage of the liver disease.
...
PMID:Progress in the enzyme diagnosis of liver disease: reality or illusion? 170 67


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>

---